MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well… Read more
MacroGenics Inc (MGNX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.451x
Based on the latest financial reports, MacroGenics Inc (MGNX) has a cash flow conversion efficiency ratio of -0.451x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.19 Million) by net assets ($67.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MacroGenics Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how MacroGenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MacroGenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MacroGenics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Attica Holdings S.A.
AT:ATTICA
|
0.023x |
|
Paik Kwang Ind
KO:001340
|
0.021x |
|
Zhuhai Kles Technology Co. Ltd. A
SHE:301314
|
N/A |
|
eMudhra Limited
NSE:EMUDHRA
|
0.013x |
|
Maider Medical Industry Equipment Co Ltd
SHG:688310
|
0.016x |
|
HeidelbergCement India Limited
NSE:HEIDELBERG
|
0.064x |
|
Motorpoint Group plc
PINK:MTPTF
|
0.055x |
|
Eclat Forever Machinery Co., Ltd.
TWO:3485
|
0.011x |
Annual Cash Flow Conversion Efficiency for MacroGenics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of MacroGenics Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $116.06 Million | $-68.37 Million | -0.589x | -14.97% |
| 2023-12-31 | $152.61 Million | $-78.20 Million | -0.512x | +16.31% |
| 2022-12-31 | $142.01 Million | $-86.96 Million | -0.612x | -2.01% |
| 2021-12-31 | $239.62 Million | $-143.83 Million | -0.600x | -58.72% |
| 2020-12-31 | $295.88 Million | $-111.90 Million | -0.378x | +35.04% |
| 2019-12-31 | $230.63 Million | $-134.27 Million | -0.582x | +7.72% |
| 2018-12-31 | $242.88 Million | $-153.23 Million | -0.631x | -1410.61% |
| 2017-12-31 | $299.24 Million | $14.40 Million | 0.048x | +129.62% |
| 2016-12-31 | $268.75 Million | $-43.68 Million | -0.163x | -272.78% |
| 2015-12-31 | $313.34 Million | $-13.66 Million | -0.044x | +83.86% |
| 2014-12-31 | $121.29 Million | $-32.76 Million | -0.270x | -50.40% |
| 2013-12-31 | $78.91 Million | $-14.17 Million | -0.180x | -122.48% |
| 2012-12-31 | $-8.24 Million | $-6.58 Million | 0.799x | +306.75% |
| 2011-12-31 | $-17.48 Million | $6.76 Million | -0.386x | -- |